# Faricimab

## Vabysmo intravitreal inj 6mg/0.05mL

| TAH Drug Code      | [IVAB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IVAB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Age-related macular degeneration， neovascular Diabetic macular edema Macular edema following retinal vein occlusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | Age-related macular degeneration， neovascular (wet): Intravitreal: Initial: 6 mg once every 4 weeks (approximately every 28 days) for 4 doses. Subsequent doses are individualized based on visual assessments， and are administered as one of the following regimens: Every-8-week regimen: 6 mg on weeks 20， 28， 36， and 44. Every-12-week regimen: 6 mg on weeks 24， 36， and 48. Every-16-week regimen: 6 mg on weeks 28 and 44. Diabetic macular edema: Doses may be administered based on one of the following regimens: Fixed interval regimen: Intravitreal: 6 mg once every 4 weeks (approximately every 28 days) for 6 doses， followed by 6 mg once every 8 weeks. Variable interval regimen: Intravitreal: 6 mg once every 4 weeks (approximately every 28 days) for at least 4 doses， followed by 6 mg every 4 to 16 weeks (based on visual assessments). Macular edema following retinal vein occlusion: Intravitreal: 6 mg once every 4 weeks (approximately every 28 days) for 6 months. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash， itching， urticaria， erythema， or severe intraocular inflammation).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Cataract (<1-15%)， Conjunctival hemorrhage (3-8%). Serious: Arterial thromboembolism (1-5%)， Raised intraocular pressure (1-4%)， Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3% (age-related macular degeneration only))， Retinal vascular occlusion， Retinal vasculitis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/faricimab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

